Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1].
References
[1] Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32(3):395-403. DOI:10.1016/j.annonc.2020.11.020
